Schubert & Co’s Catalyst Pharmaceutical CPRX Stock Holding History

Schubert & Co’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5	Closed	-$83	–	374
2023 Q1	$83	Buy	+5	New	+$82	﹤0.01%	1609

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Schubert & Co's CPRX Position: Q2 2023 in Review

Schubert & Co sold out of Catalyst Pharmaceutical (CPRX) in Q2 2023, closing a stake of 5 shares — an estimated $83 sold.

Schubert & Co first reported a position in CPRX in Q1 2023 and held it in 1 quarter. The position peaked at $83 in Q1 2023. 248 funds tracked by Wall St. Rank hold CPRX as of Q2 2023.

Schubert & Co reported no remaining Catalyst Pharmaceutical position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 5 Catalyst Pharmaceutical shares in Q2 2023, an estimated $83.
Schubert & Co first reported a position in Catalyst Pharmaceutical in Q1 2023 and held it in 1 quarter.
Schubert & Co's Catalyst Pharmaceutical position peaked at $83 in Q1 2023.
248 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.